DERM - Dermira, Inc.
| Previous Close | 11.02 |
| Open | 10.94 |
| Bid | 1.00 x 200 |
| Ask | 15.00 x 100 |
| Day's Range | 10.76 - 11.27 |
| 52 Week Range | 6.98 - 31.42 |
| Volume | 430,384 |
| Avg. Volume | 556,036 |
| Market Cap | 458.697M |
| Beta (3Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.91 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.29 |
- Simply Wall St.•4 days ago
Is Dermira Inc’s (NASDAQ:DERM) CEO Paid At A Competitive Rate?
Tom Wiggans has been the CEO of Dermira Inc (NASDAQ:DERM) since 2010. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...
- GlobeNewswire•5 days ago
Dermira Enters into Credit Facility with Athyrium Capital Management
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the closing of a $125 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare-focused investment firm. “We are pleased to be partnering with Athyrium,” said Andrew Guggenhime, chief financial officer of Dermira. “This credit facility provides us additional financial flexibility to advance our business with a focus on the ongoing launch of QBREXZA for primary axillary hyperhidrosis and the lebrikizumab program for moderate-to-severe atopic dermatitis.
- GlobeNewswire•11 days ago
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•15 days agoSee what the IHS Markit Score report has to say about Dermira Inc.
Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $274 million.
- GlobeNewswire•20 days ago
Dermira to Present at Evercore ISI HealthCONx Conference
MENLO PARK, Calif., Nov. 19, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.
- Thomson Reuters StreetEvents•last month
Edited Transcript of DERM earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 Dermira Inc Earnings Call
- GlobeNewswire•last month
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif., Nov. 08, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.
- Zacks•last month
Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates
Dermira (DERM) delivered earnings and revenue surprises of 20.20% and -10.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•last month
Dermira Reports Third Quarter 2018 Financial Results
Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to.
- GlobeNewswire•last month
Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018
MENLO PARK, Calif., Oct. 31, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.
- GlobeNewswire•2 months ago
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced the completion of patient enrollment in the Phase 2b dose-ranging study evaluating its anti-IL13 monoclonal antibody, lebrikizumab, in patients with moderate-to-severe atopic dermatitis. The company expects to announce topline efficacy and safety results from the study by early April 2019. “For many living with moderate-to-severe atopic dermatitis, the condition can often be debilitating, with patients finding limited treatment options that are effective at addressing the underlying cause of the disease,” said Luis Peña, chief development officer of Dermira.
Markit•2 months agoSee what the IHS Markit Score report has to say about Dermira Inc.
Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.77 billion over the last one-month into ETFs that hold DERM are not among the highest of the last year and have been slowing.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Dermira, California Resources, OGE Energy, Oasis Petroleum, Harmonic, and CBIZ — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on October 8, 2018, the company granted inducement awards to nine new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 8,250 shares of Dermira common stock and stock options to purchase an aggregate of 44,825 shares of Dermira common stock.
- GlobeNewswire•2 months ago
Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced its collaboration with Council of Fashion Designers of America, Inc. (CFDA) fashion designer Christian Siriano for the Check Your Sweat educational campaign. Check Your Sweat is designed to raise awareness of excessive underarm sweating, or primary axillary hyperhidrosis, a treatable medical condition.
- GlobeNewswire•2 months ago
Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today that QBREXZA™ (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.
Markit•2 months agoSee what the IHS Markit Score report has to say about Dermira Inc.
Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding DERM is favorable, with net inflows of $5.36 billion.
- GlobeNewswire•2 months ago
Dermira to Present at Cantor 2018 Global Healthcare Conference
MENLO PARK, Calif., Sept. 25, 2018-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...
- GlobeNewswire•3 months ago
Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today presented data from a post-hoc analysis of the Phase 3 open-label ARIDO study which evaluated the long-term safety of glycopyrronium tosylate in patients with primary axillary hyperhidrosis. The data showed the response of pediatric patients (ages 9 to 16) compared to older patients (ages 17 years and older) with primary axillary hyperhidrosis who received treatment with glycopyrronium tosylate (now QBREXZA™ (glycopyrronium) cloth).
Markit•3 months agoSee what the IHS Markit Score report has to say about Dermira Inc.
Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold DERM had net inflows of $499 million over the last one-month.
Markit•3 months agoSee what the IHS Markit Score report has to say about Dermira Inc.
Short interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $1.01 billion.
